
Description:
1.IntendedUse TheGenWayEBVEBNA-1IgAAntibodyELISATestKithasbeendesignedforthethedetection andthequantitativedeterminationofspecificIgAantibodiesagainstEBVEBNA-1inserumand plasma.FurtherapplicationsinotherbodyfluidsarepossIBLeandcanberequestedfromthe TechnicalServiceofGenWay. Thisassayisintendedforresearchuseonly.
2.GeneralInformation In1961aninfectiousdiseasewasidentifiedinUganda,whichwascorrelatedwiththeappearance ofadefinedtypeoftumorwithchildren.Theillness,whichisfoundpredominantlyinAfricaand Papua-NewGuinea,wasnamedBurkittlymphomafromitsdiscoverer.TheEpsteinBarrvirusis maderesponsibleforavarietyofdiseaseslikeinfectiousmononucleosis,Burkittlymphoma,aswell asnasopharyngealcarcinoma.Inaddition,arole ofthevirusisdiscussedinconnectionwith Hodgkin´sdisease.Especiallywithteenagersthereappearsaglandularfeversyndrome,whichis called&BDquo;kissingdisease“.DiseaseswhicharecausedbytheEpsteinBarrvirusarefoundmainlyin personswithreducedimmunity.Forexample,the virusisassociatedwithalymphoproliferative diseasewhichoccursaftertransplantation.Theimmunesystemofsuchindividualsisusually impairedbydrugtherapy.Alsoinimmune-deficientAIDSaffectedindividuals,thereappears frequentlyastatewherecellsattherimofthetongueareinfected(oralhairyleukoplakia).Infected personskeeptheEpstein-Barrvirusforeverintheirbody,theyarehowevermostlynotill.Inthe developingcountriespracticallyallthepeopleareinfected,inthewesternworldtheincidenceis between80%and90%.Thetransmittanceoccursalreadyduringchildhood,perhapsbytransfer fromthemother,mainlyviathesaliva.Duringtheactivephaseoftheviralcycle,theEpstein-Barr virusproducesabout100differentantigens,intheinactivephasearound10.Thelattercomprises amongotherstheEBVnuclearantigenEBNA-1,whichiscloselycorrelatedwithapastinfection andanimmunity.Theearlyantigen(EA)aswellastheviruscapsidantigen(VCA)fromtheactive phasearealsousedasdiagnosticMarkers.Inafreshinfection,IgMantibodiesagainstVCAandEA aredeterminedbyimmunofluorescenceorELISA.LaterVCAIgGandafterwardsEBNA-1IgG antibodiesappear.ThesimultaneousactivationofVCAIgMandEBNA-1IgGindicates correspondinglyareactivationofalatentEBVinfection.TheImmunolabEBNA-1IgGELISA monitorsapastinfectionsatisfactorilyandcanbeutilizedfortheassessmentofbloodsamples beforetransfusionsortransplantationsandtheexclusionoftransmittancebetweenchildren.
3.PrincipleoftheTest TheGenWayEBVEBNA-1IgAantibodytestkitisbasedontheprincipleoftheenzyme immunoassay(EIA).EBVEBNA-1antigenisboundonthesurfaceofthemicrotiterstrips.Diluted sampleserumorready-to-usestandardsarePipettedintothewellsofthemicrotiterplate.Abinding betweentheIgAantibodiesoftheserumandtheimmobilizedEBVEBNA-1antigentakesplace. Afteraonehourincubationatroomtemperature,theplateisrinsedwithdilutedwashsolution,in ordertoremoveunboundmaterial.Thenready-to-useanti-human-IgAperoxidaseconjugateis addedandincubatedfor30minutes.Afterafurtherwashingstep,thesubstrate(TMB)solutionis pipettedandincubatedfor20minutes,inducingthedevelopmentofabluedyeinthewells.The colordevelopmentisterminatedbytheadditionofastopsolution,whichchangesthecolorfrom bluetoyellow.Theresultingdyeismeasuredspectrophotometricallyatthewavelengthof450nm. TheconcentrationoftheIgAantibodiesisdirectlyproportionaltotheintensityofthecolor.
AdditionalInformation:
Name | EBVEBNA-1IgAELISA |
---|---|
RelatedProductNames | EBVEBNA-1IgAELISA |
IntendedUse | ResearchUseOnly |